AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36059138
Drug: Constant infusion
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant infusion of ceftaroline 50 mg/h after a loading dose of 600 mg
Trial: 36059450
Drug: Neoadjuvant immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant immunotherapy (24 patients)
Trial: 36059450
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (16 patients)
Trial: 37655106
Drug: Neoadjuvant targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant targeted therapy (9 patients)
Trial: 36060221
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin A supplements and vitamin A-fortified foods
Trial: 36061336
Drug: Aficamten (≤50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aficamten (≤50 mg single doses or ≤10 mg daily for 14 or 17 days)
Trial: 36061421
Drug: Trans-obturator tape
RxNorm normalized name: TAPE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trans-obturator tape intervention, details on dosage and duration not available
Trial: 36061598
Drug: 4-day accelerated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-day accelerated continuous theta burst stimulation (cTBS) treatment
Trial: 36062026
Drug: Natalizumab followed
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Natalizumab followed by alemtuzumab sequential therapy
Trial: 36062451
Drug: Remote patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote patient management (RPM) with daily measurements of vital parameters under guidance of HF nurses.
Trial: 36062451
Drug: Remote patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote patient management (RPM) with daily measurements of vital parameters.
Trial: 36063533
Drug: Oral testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testing and provider-assisted confidential partner notification.
Trial: 36064386
Drug: Sintilimab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab (200 mg) plus docetaxel (75 mg/m2)
Trial: 36064670
Drug: IPV-Al (aluminium-adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPV-Al (aluminium-adjuvanted reduced dose inactivated polio vaccine)
Trial: 36064725
Drug: Miglustat use
RxNorm normalized name: Miglustat
DrugBank: Miglustat (DB00419)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Miglustat use (a glucosylceramide synthase inhibitor)
Trial: 36064748
Drug: Guided imagery
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided imagery for treatment (GIFT) - a brief, two-session guided imagery intervention.
Trial: 36064748
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) - control group.
Trial: 36066745
Drug: Odevixibat treatment
RxNorm normalized name: Odevixibat
DrugBank: Odevixibat (DB16261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Odevixibat treatment for 24 weeks
Trial: 36066903
Drug: Methylprednisolone pulse
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone pulse 15 mg/kg/day for 3 days followed by oral prednisone 1 mg/kg/day
Trial: 36066903
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone 1 mg/kg/day alone
Trial: 36067063
Drug: Daratumumab subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab subcutaneous (DARA SC) 1800 mg every 4 weeks
Trial: 36067139
Drug: Physiotherapy interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Physiotherapy interventions recommended by physiotherapists (education, spinal exercises, manual therapy)
Trial: 36067139
Drug: Passive physiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Passive physiotherapy approaches prescribed by general practitioners (massage therapy, electrotherapy)
Trial: 36068495
Drug: FOLFOXIRI (5-fluorouracil,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOXIRI (5-fluorouracil, leucovorin, oxaliplatin, and irinotecan) administered for six two-weekly cycles prior to chemoradiotherapy.
Trial: 36068858
Drug: Vortioxetine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine treatment for MDD (6 months)
Trial: 36068950
Drug: Bispecific LV20.19
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bispecific LV20.19 CAR T-cell therapy at a target dose of 2.5 × 10^6 cells/kg
Trial: 36069336
Drug: Pan-enteric capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pan-enteric capsule endoscopy (CE)
Trial: 36069495
Drug: rFSH (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rFSH (150 IU daily)
Trial: 36070176
Drug: Quadrivalent inactivated
RxNorm normalized name: Fluarix Quadrivalent 2018-2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent inactivated split-virion influenza vaccine (QIV; Vaxigrip Tetra)
Trial: 36070539
Drug: UCPVax (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UCPVax (0.25 mg, 0.5 mg, and 1 mg)
Trial: 36070540
Drug: Pafolacianine (0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pafolacianine (0.025 mg/kg IV), given ≥ 1 hour before intraoperative near-infrared imaging
Trial: 36072945
Drug: Analytic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analytic treatment interruption (ATI)
Trial: 36072994
Drug: Burosumab (0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Burosumab (0.3, 0.6, or 1.0 mg/kg subcutaneous injection every 4 weeks, titrated at Week 12)
Trial: 36073648
Drug: Serum drug
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum drug measurements
Trial: 36073648
Drug: Directly observed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directly observed therapy
Trial: 36074550
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (5 times/week)
Trial: 36074550
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (1 time/week)
Trial: 36075501
Drug: CC criteria
RxNorm normalized name: DIMETHICONE 1 g in 100 mL TOPICAL GEL [JAFRA Fruteria So Citrico]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC criteria for PEP
Trial: 36075560
Drug: Scout Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scout Dose Resin Yttrium-90 Microspheres
Trial: 36076205
Drug: Therapeutic Assertive
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic Assertive Community Treatment
Trial: 36077617
Drug: BMS-986158 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-986158 (5 days on, 2 days off; 0.75-4.5 mg)
Trial: 36077617
Drug: BMS-986158 (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-986158 (14 days on, 7 days off; 2.0-3.0 mg)
Trial: 36077617
Drug: BMS-986158 (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-986158 (7 days on, 14 days off; 2.0-4.5 mg)
Trial: 36078407
Drug: Waist girth-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waist girth-based equations (e.g., relative fat mass)
Trial: 36081609
Drug: Mind-body medicine
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mind-body medicine (MBM) program, weekly 6-h session for 10 weeks
Trial: 36081814
Drug: EA plus
RxNorm normalized name: Finacea Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EA plus high-dose DCPA (4 mg)
Trial: 36081814
Drug: EA plus
RxNorm normalized name: Finacea Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EA plus low-dose DCPA (2 mg)
Trial: 36082269
Drug: Tafamidis treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafamidis treatment for 24 months
Trial: 36082554
Drug: Neoadjuvant hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant hormonal therapy (NHA) prior to radical prostatectomy (RP)
Trial: 36082616
Drug: ONO-4578, an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONO-4578, an antagonist of prostaglandin E, specific dosage and duration not available
Trial: 36083035
Drug: Chemotherapy (anthracycline-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (anthracycline-containing regimens)
Trial: 36083129
Drug: AVD chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVD chemotherapy (doxorubicin, vinblastine, and dacarbazine)
Trial: 36083129
Drug: Sequential pembrolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential pembrolizumab and AVD
Trial: 36083174
Drug: Comorbidity count
RxNorm normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comorbidity count (CC)
Trial: 36083313
Drug: Avelumab plus
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab plus autologous dendritic cell vaccine
Trial: 36083982
Drug: Second tertile
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second tertile of baseline plasma Se (74.5 to < 89.4 μg/L)
Trial: 36083982
Drug: Highest tertile
RxNorm normalized name: textiles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest tertile of baseline plasma Se (89.4 to <150 μg/L)
Trial: 36084395
Drug: Trastuzumab emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab emtansine (T-DM1) 3.6 mg/kg, administered intravenously every 3 weeks
Trial: 36084396
Drug: eprenetapopt (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eprenetapopt (4.5 g/day IV on days 1-4) plus pembrolizumab (200 mg IV on day 3 in each 21-day cycle)
Trial: 36085059
Drug: Intramuscular vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vitamin A
Trial: 36085337
Drug: PROMs questionnaires
RxNorm normalized name: MENTHOL 5.5 g in 100 g / BORNEOL 6.25 g in 100 g / CINNAMOMUM CAMPHORA LEAF 12.5 g in 100 g / BARLERIA LUPULINA WHOLE 12.5 g in 100 g TOPICAL PATCH [Wang Prom Green Balm by Wang Prom]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PROMs questionnaires (Euro Quality 5 Dimensions 3L, EQ-5D-3L, Euro-Quality-Visual-Analytic-Score, EQ-VAS, Hip disability and Osteoarthritis Outcome Score, HOOS-PS) administered pre-operatively, at 6 months, and at 12 months after surgery.
Trial: 36087148
Drug: Evaluation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluation of clinical, biological, neurophysiological, neuropsychological, and imaging biomarkers
Trial: 36087223
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment for GERD
Trial: 36088907
Drug: Drug-Induced Acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-Induced Acute Kidney Injury (DI-AKI) risk prediction models
Trial: 36088907
Drug: Statistical methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statistical methods (e.g., least absolute shrinkage and selection operator regression, advanced machine learning techniques)
Trial: 36089112
Drug: GST-HG131, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GST-HG131, a novel HBV antigen inhibitor
Trial: 36089578
Drug: UV1 vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UV1 vaccination and ipilimumab treatment
Trial: 36089621
Drug: Single antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single antiplatelet therapy (APT) + Oral anticoagulation (OAC)
Trial: 36090637
Drug: Pemetrexed plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed plus cisplatin (Pem-Cis); 500 mg/m2 of pemetrexed administered for four cycles in 99 patients (94.3%).
Trial: 36092320
Drug: Erlotinib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib and proton therapy
Trial: 36093342
Drug: Single fraction
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single fraction of high-dose rate brachytherapy (HDB) 20 Gy
Trial: 36093738
Drug: Elezanumab 50-1,600mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elezanumab 50-1,600mg IV and 150mg subcutaneous
Trial: 36094733
Drug: Follicular group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follicular group (mean serum MOR levels: 275 ± 32 pg/ml)
Trial: 36094733
Drug: Luteal group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteal group (mean serum MOR levels: 254 ± 28 pg/ml)
Trial: 36094804
Drug: Constant Therapy
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant Therapy (tablet-based training)
Trial: 36094839
Drug: Cemiplimab (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cemiplimab (350 mg every 3 weeks for up to four doses)
Trial: 36095841
Drug: Itacitinib 200
RxNorm normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itacitinib 200 mg/d for 28 days
Trial: 36095841
Drug: SCS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCS treatment
Trial: 36095849
Drug: Cilta-cel infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilta-cel infusion after lymphodepletion
Trial: 36096442
Drug: Brigatinib 180
RxNorm normalized name: brigatinib 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brigatinib 180 mg once daily (after 7-day 90-mg lead-in)
Trial: 36096442
Drug: Brigatinib 180
RxNorm normalized name: brigatinib 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brigatinib 180 mg once daily (after 7-day 90-mg lead-in) in patients with ctDNA-detectable baseline ALK fusion (n=64)
Trial: 36096442
Drug: Brigatinib 180
RxNorm normalized name: brigatinib 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brigatinib 180 mg once daily (after 7-day 90-mg lead-in) in patients who progressed on alectinib (n=86)
Trial: 36096532
Drug: BND-22 (ILT2-blocking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BND-22 (ILT2-blocking antibody)
Trial: 36096940
Drug: Group Metacognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Metacognitive Therapy (MCT), up to eight sessions delivered by a CAMHS mental health practitioner
Trial: 36096940
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care in CAMHS (individual or group-based therapy)
Trial: 36097216
Drug: neoadjuvant atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: neoadjuvant atezolizumab monotherapy
Trial: 36097345
Drug: GSK1795091 (modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1795091 (modified formulation)
Trial: 36097345
Drug: GSK1795091 (original
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1795091 (original formulation)
Trial: 36097345
Drug: GSK1795091 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1795091 (both formulations)
Trial: 36097602
Drug: Asfotase alfa
RxNorm normalized name: Asfotase alfa
DrugBank: Asfotase alfa (DB09105)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Asfotase alfa (enzyme replacement therapy)
Trial: 36097844
Drug: BNT162b2 mRNA
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 mRNA vaccine (fourth dose)
Trial: 36098320
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus ipilimumab (nivolumab 240 mg every 2 weeks and ipilimumab 1 mg/kg every 6 weeks)
Trial: 36098320
Drug: Nivolumab alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab alone (240 mg every 2 weeks)
Trial: 36099010
Drug: Single-patch 12-lead
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-patch 12-lead ECG (SP-ECG)
Trial: 36100318
Drug: Cocoa (dark
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa (dark chocolate) 30 g/day for 1 week
Trial: 36100355
Drug: Intranasal nalbuphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal nalbuphine (0.1 mg/kg)
Trial: 36100355
Drug: Intravenous nalbuphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nalbuphine (0.05 mg/kg)
Trial: 36100698
Drug: Steroid quantitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid quantitation
Trial: 36101520
Drug: ROS1-selective inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ROS1-selective inhibitors
Trial: 36101656
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 10 mg orally
Trial: 36103643
Drug: MTB-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTB-directed therapy (both on-label and off-label therapies)
Trial: 36103643
Drug: MTB-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTB-directed therapy
Trial: 36104359
Drug: camrelizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: camrelizumab (200 mg, q2w) and apatinib (250 mg, once daily)
Trial: 36104795
Drug: Elraglusib (9-ING-41)
RxNorm normalized name: Elraglusib
DrugBank: Elraglusib (DB16047)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elraglusib (9-ING-41) as a single agent
Trial: 36104795
Drug: Elraglusib (9-ING-41)
RxNorm normalized name: Elraglusib
DrugBank: Elraglusib (DB16047)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elraglusib (9-ING-41) in combination with anti-PD-1 mAb
Trial: 36104795
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy with elraglusib and anti-PD-1 mAb
Trial: 36105230
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine intervention
Trial: 36105914
Drug: Ruxolitinib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib at the maximum safe starting dose (MSSD) of 10 mg bid
Trial: 36105925
Drug: Remotely controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remotely controlled mandibular positioner (RCMP) titration during in-lab sleep study
Trial: 36107220
Drug: Famitinib 25
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Famitinib 25 mg
Trial: 36107221
Drug: BCMA-CART cell
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCMA-CART cell therapy
Trial: 36107363
Drug: Prophylactic beta-blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic beta-blockers
Trial: 36107394
Drug: Zandelisib (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zandelisib (45 or 60 mg daily)
Trial: 36107483
Drug: Systemic treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic treatment based on genetic analyses of tumor tissue
Trial: 36108256
Drug: In-home rapid
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-home rapid antigen COVID-19 testing (BinaxNOW), administered twice weekly for three months.
Trial: 36108259
Drug: Dual HER2-targeted
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dual HER2-targeted therapy (trastuzumab plus pertuzumab)
Trial: 36108259
Drug: Standard-of-care neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care neoadjuvant chemotherapy with trastuzumab
Trial: 36108304
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) JZP458 25/25/50 mg/m2 MWF
Trial: 36108304
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) JZP458 25 mg/m2 MWF
Trial: 36108304
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) JZP458 37.5 mg/m2 MWF
Trial: 36108308
Drug: Rondaptivon pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rondaptivon pegol (3 mg on days 0 and 4, then weekly doses of 2 to 9 mg until day 28)